- The American Academy of Ophthalmology (AAO) cancelled its in-person annual meeting scheduled to take place in November in Las Vegas and will present a virtual-only event. According to a statement on the AAO website, “In light of epidemiological projections, government regulations and public health mandates to prevent the spread of disease—including social distancing, limited crowd sizes and face coverings—the Academy has been forced to cancel its in-person annual meeting this year.” The AAO said it will send more information by Aug. 12 about options regarding refunds, applying payments to the virtual meeting and transferring registration to the 2021 meeting in New Orleans.
- TearLab Corporation announced its acquisition by Accelmed Partners II. As a newly formed private company, TearLab is now positioned to pursue further development of its Discovery platform and seek out targeted acquisition opportunities that support a comprehensive portfolio to better meet DED market dynamics and patient care needs, the company says.
- Alcon’s Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, received FDA approval for sale over-the-counter (OTC). Pataday Once Daily Relief Extra Strength is the first and only once daily eye allergy itch drop offering a full 24 hours of relief without a prescription, according to Alcon. This formulation joins Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%), which were approved for sale OTC in February 2020.
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here.